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ABSTRACT
Thioredoxin-1 (Trx1) protects the heart from ischemia/reperfusion (I/R) injury. 
Given that the age at which the first episode of coronary disease takes place has 
considerably decreased, life at middle-aged (MA) emerges as a new field of study. 
The aim was determine whether infarct size, Trx1 expression and activity, Akt and 
GSK-3β were altered in young (Y) and MA mice overexpressing cardiac Trx1, and in 
a dominant negative (DN-Trx1) mutant of Trx1. Langendorff-perfused hearts were 
subjected to 30 minutes of ischemia and 120 minutes of reperfusion (R). We used 3 
and 12 month-old male of wild type (WT), Trx1, and DN-Trx1. Trx1 overexpression 
reduced infarct size in young mice (WT-Y: 46.8±4.1% vs. Trx1-Y: 27.6±3.5%, p < 
0.05). Trx1 activity was reduced by 52.3±3.2% (p <  0.05) in Trx1-MA, accompanied 
by an increase in nitration by 17.5±0.9%, although Trx1 expression in transgenic mice 
was similar between young and middle-aged. The expression of p-Akt and p-GSK-
3β increased during reperfusion in Trx1-Y. DN-Trx1 mice showed neither reduction 
in infarct size nor Akt and GSK-3β phosphorylation. Our data suggest that the lack 
of protection in Trx1 middle-aged mice even with normal Trx1 expression may be 
associated to decreased Trx1 activity, increased nitration and inhibition of p-Akt and 
p-GSK-3β.
INTRODUCTION
Thioredoxin-1 (Trx1) is one of the most important 
cellular antioxidant systems known to date [1]. 
Particularly, Trx1 exerts an increase in lifespan and has a 
protective effect against ischemia/reperfusion (I/R) injury, 
reducing the infarct size [2-4]. In this sense, Nakamura 
et al. [5] showed in patients subjected to bypass surgery 
that thioredoxin inactivation was a deleterious mechanism 
in I/R injury. Similarly, Tao et al. [3] showed that 
administration of Trx1 in vivo exerts significant protective 
effects on myocardial apoptosis decreasing myocardial 
infarct size, by inhibiting p38-MAPK activation. Thus, it 
is clear that Trx1 has a protective effect against I/R injury. 
However, most of these studies were performed in young 
and healthy rodents [2-4]. 
It is also widely known that I/R injury is exacerbated 
in elderly populations and that many of the protective 
mechanisms lose their effect with advanced age [6, 7]. 
But it is not clear whether this also occurs in middle-aged, 
when the deleterious effects of aging are already taking 
place [8, 9]. This lack of studies in middle-aged is striking, 
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since ischemic episodes in patients begins at that stage of 
life, and they are not exclusive of advanced age [8, 9]. 
There are numerous experimental evidence showing that 
mice older than 18 months exhibit a significant increment 
in reactive oxygen and nitrogen species (ROS and RNS) 
thus exacerbating I/R damage [6, 7]. Regarding Trx1 
and aging, it has been demonstrated that infarct size and 
apoptosis increase in older animals due to thioredoxin 
physiological inactivation [10, 11]. However, it is known 
that even though oxidation processes start when life 
begins; it is in middle-aged that they reach sufficient 
levels to trigger deleterious mechanisms on different cell 
components [12], and this ROS increases is able to modify 
expression and/or activity of several proteins [13-15]. 
However if Trx1, at this stage of life, suffers alterations in 
its expression and/or activity has not been studied, neither 
have modifications in the infarct size behavior.
It has been also widely demonstrated that the 
activation of the PI3K/Akt complex triggers intracellular 
events, such as the inactivation of glycogen synthase 
kinase 3β (GSK-3β) [16]. This is a consequence of its 
phosphorylation by Akt, which confers protection against 
I/R damage, decreasing the infarct size [16-18]. Adluri et 
al. [19] showed that Trx1 overexpression induces Akt-
signaling pathway compared to wild type mice during 
ischemic stress, and this could be related to a reduction in 
oxidative stress. Regarding GSK-3β and Trx1, Schenkel 
et al. [20] report that in later stages there is a decrease of 
Trx1 in parallel with some signaling proteins, including 
GSK-3β activation that is involved in maladaptative 
cardiac remodeling and ventricular dysfunction. For these 
reasons, it would be interesting to study the activation/
inactivation of Akt and GSK-3β in an acute I/R protocol 
with overexpression of Trx1, and to compare the results 
between young and middle-aged mice. 
Thus, the first objective of our work was to evaluate 
infarct size and ventricular function in young and also in 
middle-aged transgenic (TG) mice overexpressing Trx1. 
To further study the role of Trx1 in cardioprotection, 
we also use a dominant negative (DN-Trx1) mutant 
(C32S/C35S) of Trx1, with cardiac overexpression and 
inactivation of Trx1. Since Trx1 presents a decrease 
in activity and protein nitration in older mice, a second 
objective was to determine if middle-aged TG mice 
overexpressing Trx1 also present an increase in these 
inactivation mechanisms. Finally, a third objective was to 
examine if the protection conferred by Trx1 involves Akt 
and GSK-3β inhibition/phosphorylation.
RESULTS
Table 1 shows the systolic behavior throughout 
the left ventricular developed pressure (LVDP, mmHg) 
and the maximal rate of rise of left ventricular pressure 
Table 1: Left ventricular systolic and diastolic function.
Groups Baseline 30min Rep
LVDP 
(mmHg)
Wt-Y 88.2 ± 2.3 27.9 ± 4.7*
Wt-MA 80.5 ± 8.5 22.1 ± 7.8*
Trx1-Y 87.7 ± 6.6 30.6 ± 3.5*
Trx1-MA 87.1 ± 7.8 29.2 ± 7.7*
DN-Trx1-Y 91.2 ± 5.4 32.4 ± 5.2*
DN-Trx1-MA 92.7 ± 8.2 31.9 ± 4.7*
LVEDP 
(mmHg)
                                    
Wt-Y 7.8 ± 1.1 28.5 ± 5.8*
Wt-MA 8.8 ± 2.8 30.2 ± 8.5*
Trx1-Y 7.1 ± 0.8 21.4 ± 7.1*
Trx1-MA 7.6 ± 1.1 23.3 ± 6.6*
DN-Trx1-Y 8.2 ± 1.8 34.5 ± 4.2*
DN-Trx1-MA 8.5 ± 0.9 29.4 ±3.9 *
LV+dP/dtmax 
(mmHg/sec)
Wt-Y 3151 ± 206 1285 ± 196*
Wt-MA  2949 ± 217 1199 ± 257*
Trx1-Y 2927 ± 301 1399 ± 128*
Trx1-MA 3228 ± 339 1320 ± 239*
DN-Trx1-Y 3308 ± 287 1289 ± 117*
DN-Trx1-MA 3189 ± 294 1229  ±133*
LVDP: Left ventricular developed pressure; LVEDP: Left ventricular end diastolic 
pressure; LV+dP/dtmax: Left ventricular maximal rate of pressure increase. Rep: 
Reperfusion. *: p<0.05 vs respective baseline value. Wt: wild type; Trx1: transgenic 
mice thioredoxin-1 overexpression; DN-Trx1: Dominant negative for endogenous 
Trx1 in mice hearts Y: Young; MA: middle-aged.
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(LV+dP/dtmax), at baseline and 30 minutes of reperfusion. 
In all groups, LVDP and LV+dP/dtmax were significantly 
lower compared to pre-ischemic values, but showed 
no significant differences among groups. Regarding 
myocardial stiffness, represented by the left ventricular 
end of diastolic pressure (LVEDP, mmHg), we found a 
significant increase at 30 minutes of reperfusion respective 
pre-ischemic values without changes among the groups.
Figure 1 (Panel A) shows the infarct size in 
all experimental groups. The Trx1 overexpression 
significantly reduced the infarct size in young mice (WT-
Y: 52.3±3.2% vs. Trx1-Y: 27.6±3.5%, p < 0.05), while 
middle-aged animals did not exhibit this infarct size 
reduction (WT-MA: 51.8±2.6% vs. Trx1-MA: 49.1±6.3%). 
Panel B shows representative slices of the different 
experimental groups.
Figure 2 shows the behavior of Trx1 expression 
(Panel A), activity (Panel C) and nitration (Panel D). 
In normoxic conditions in young and middle-aged TG 
mice there were a significant increase in Trx1 expression 
(Panel A), meanwhile Trx1 levels were lesser in WT 
middle-aged than in young mice (Nx-Y:1.1±0.1 vs. Nx-
MA: 0.42±0.05, p < 0.05). At 15 minutes of reperfusion, 
Trx1 expression decreased significantly in wild type mice 
reaching a 47% in young and 42 % in middle-aged of 
reduction compared with pre-ischemic values (Panel A), 
and in TG mice Trx1 levels was similar to their respective 
normoxic values. Trx1 activity was reduced in Trx1-MA 
compared with Trx1-Y mice (Panel C). Directly related to 
the previous findings, there was a 17.5±0.9% increase in 
the nitration of Trx1-MA mice compared to Trx1-Y (Panel 
D).Taken together, these data suggest that in Trx1 middle-
aged mice, even with normal Trx1 expression, there is 
inactivation of Trx1 that involves protein nitration. Panel 
B shows ponceau S-stained blot, as loading control, and 
representative blots of Trx1.
Figure 3 shows the cardiac expression of Akt 
phosphorylation at Ser473 residue, in the cytosolic 
fraction in normoxic conditions (matched time) and 
after ischemia/reperfusion (15 minutes of reperfusion) in 
young (Panel A) and middle-aged mice (Panel B). Panel 
C shows representative blots and ponceau S-stained blot 
of total and phosphorylated Akt. We showed a significant 
increase in p-Akt Ser473 in the group of young animals 
with overexpression of Trx1 during reperfusion compared 
to pre-ischemic values (Trx1-Y; normoxic: 1.02±0.07 
AU vs. I/R: 1.47±0.08 AU; p < 0.05), meanwhile in WT 
young group there were no changes at reperfusion period 
(Panel A). Nevertheless, p-Akt Ser473 values in middle-
aged mice were similar between wild type and Trx1 before 
ischemia and during reperfusion (I/R: WT-MA 0.97±0.14 
AU vs. Trx1-MA 0.86±0.10 AU) (Panel B). Thus, our data 
shows an increase in p-Akt Ser473 phosphorylation in 
Trx1-Y mice hearts while there is no increase in middle-
aged ones. Regarding p-Akt Thr308 site (data not shown), 
there were no significant differences within the groups of 
young animals before ischemia and during reperfusion and 
middle-aged animals. 
Figure 4 shows the cardiac expression of p-GSK-
3β Ser9 residue, in the cytosolic fraction in normoxic 
conditions and after ischemia/reperfusion (15 minutes 
of reperfusion in young (Panel A) and middle-aged mice 
(Panel B). It can be observed that there are no significant 
differences in the expression of total GSK-3β among all 
the groups studied (Panel C), while a significant increase 
of p-GSK-3β is observed in the group of young animals 
Figure 1: Infarct size expressed as a percentage of the total left ventricular area. Infarct size decreased significantly in 
Trx1 young group but this cardioprotective effect was abolished in Trx1 middle-aged. Panel B shows representative slices of the different 
experimental groups. Data are represented as mean +/- SEM. *: p < 0.05 vs. WT-Y. WT-Y: wild type in young animals (3 month-old); WT-
MA: wild type in middle-aged animals (12 month-old); Trx1-Y: thioredoxin-1 young group; Trx1-MA: thioredoxin-1 middle-aged group.
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Figure 2: Panel A shows an increased in Trx1 expression in transgenic animals, both in young (Y) and middle-aged 
(MA) group in normoxic (Nx) conditions and after ischemia/reperfusion protocol. The levels of Trx1 in wild type mice (WT) 
decreased at reperfusion (after 30 minutes of ischemia and 15 minutes of reperfusion) in young and middle-aged animals, but in transgenic 
mice the levels of Trx1 remains in similar values as normoxic conditions. Panel B show Ponceau S-stained blot, as loading control, and 
representative blots of Trx1. Panel C shows that in transgenic mice the activity was lower in Trx1 young group compared with Trx1 middle-
aged group. Finally, in panel D we observed an increased in Trx1 nitration in middle-aged group compared with young group. Data are 
represented as mean +/- SEM. *: p < 0.05 vs. WT animals. #: p < 0.05 vs. Nx respective conditions; &: p < 0.05 vs. Trx1 young group.
Figure 3: Akt phosphorylation (Ser 473) protein expression in the cytosolic fraction of normoxic (Nx) and ischemia/
reperfusion protocols (I/R) in young (Panel A) and middle-aged (Panel B) mice. There were not significantly changes in the 
cytosolic Akt protein expression (Panel C). Also, not significantly changes were detected, in the cytosolic p-Akt Ser 473 protein expression 
in Trx1 and WT middle-aged groups, however in Trx1 young group a significantly enhanced of Akt phosphorylation after I/R was detected. 
Panel C shows Ponceau S-stained blot, as loading control, and representative blots of total and phosphorylated Akt. Data are represented as 
mean +/- SEM. *: p < 0.05 vs normoxic Trx1; #: p < 0.05 vs WT-Y I/R. WT-Y: wild type in young animals (3 month-old); WT-MA: wild 
type in middle-aged animals (12 month-old); Trx1-Y: thioredoxin-1 young group; Trx1-MA: thioredoxin-1 middle-aged group.
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overexpressing Trx1 compared with its pre-ischemic value 
(Trx1-Y: normoxic: 1.01±0.01 AU vs. I/R: 1.30±0.10 AU, 
p < 0.05) (Panel A). However, this increase in the GSK-
3β phosphorylation is not evidenced in the middle-aged 
groups, both in WT mice and in Trx1 mice (WT-MA: 
normoxic: 1.02±0.14 AU; I/R: 1.13±0.1 AU; Trx1-MA: 
normoxic: 1.08±0.09 AU; I/R: 1.23±0.13 AU) (Panel 
B). Panel C represents representative blots and ponceau 
S-stained blot of total and p-GSK-3β. 
In order to confirm that cardioprotection afforded 
by Trx1 involved Akt and GSK-3β phosphorylation, 
additional experiments in DN-Trx1 mice with cardiac 
overexpression of a redox inactive Trx1 mutant were 
performed. We detected that infarct size was similar 
between WT and DN-Trx1 in young (WT-Y: 52.3±3.2% 
vs. DN-Trx1-Y: 54.3±4.0%) and in middle-aged mice 
(WT-MA: 51.8±2.6% vs. DN-Trx1-MA: 56.6±4.2%). 
The Akt and GSK-3β phosphorylation in young and also 
in middle-aged DN-Trx1 did not show changes between 
basal and ischemia /reperfusion conditions. These results 
are consistent with the lack of cardioprotection in DN-
Trx1 mice (Figure 5).
DISCUSSION
The present study shows, as expected, that young 
mice overexpressing Trx1 have a smaller infarct size 
compared to their corresponding WT mice. However, 
this infarct size reduction was observed neither in Trx1 
middle-aged nor in young and middle-aged DN-Trx1 
mice. Although we found a significant increase in Trx1 
levels in young and middle-aged transgenic mice, Trx1 
activity was less in middle-aged mice and this findings was 
accompanied by an increase in the nitration of this protein. 
Finally, we also demonstrated that phosphorylation of Akt 
and GSK-3β were increased only in young Trx1 mice 
without any change in middle-aged mice and in DN-Trx1 
mice.
Since we did not evidence infarct size reduction in 
middle-aged Trx1 mice, we mesaured Trx1 expression 
and activity in these animals. After ischemia/reperfusion 
protocol in WT mice we evidenced a significant reduction 
in Trx1 levels both in young and middle-aged animals. 
With regard to our findings, other authors have evidenced 
that during reperfusion after an ischemic period, there is 
an increase in peroxynitrite concentration, and it has been 
reported to produce cellular damage by lipid peroxidation, 
DNA fragmentation, and in addition induced depletion of 
antioxidants [21, 22] including thioredoxin [6]. However, 
in mice overexpressing thioredoxin we evidenced that 
during reperfusion Trx1 levels were similar to pre-
ischemic values. Although protein levels remained intact, 
Figure 4: pGSK-3β Ser 9 protein expression in the cytosolic fraction of normoxic (Nx) and ischemia/reperfusion 
protocols (I/R) in young (Panel A) and middle-aged (Panel B) mice. There were not significantly changes in the cytosolic 
GSK-3β protein expression (Panel C). Also, not significantly changes in the cytosolic in p-GSK-3β Ser 9 protein expression were detect 
in Trx1and WT middle-aged groups, however in Trx1 young group, a significantly enhanced of GSK-3β phosphorylation after I/R was 
detected. Panel C shows Ponceau S-stained blot, as loading control, and representative blots. Data are represented as mean +/- SEM. *:p 
< 0.05 vs normoxic Trx1; #: p < 0.05 vs WT-Y I/R. WT-Y: wild type in young animals (3 month-old); WT-MA: wild type in middle-aged 
animals (12 month-old); Trx1-Y: thioredoxin-1 young group; Trx1-MA: thioredoxin-1 middle-aged group.
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we found a decrease in Trx1 activity with an increase 
nitration, only in middle-aged mice. It is well known, that 
thioredoxin can suffer post-translational modifications 
such as S-nitrosylation, oxidation and nitration [23, 1, 10, 
24]. The first one has beneficial effects improving Trx1 
cardioprotective activity through apoptosis reduction [23]. 
Oxidation partially inactivates it while nitration causes 
Trx1 totally irreversible inactivation resulting in the 
attenuation of its biological functions [1, 10, 24]. Thus, 
it is clear that in our study the increase in Trx1 nitration 
produced the reduction in its activity and consequently 
there was no evidence of the beneficial effects on middle-
aged mice infarct size. As previously mentioned, Zhang 
et al. [11] demonstrated that Trx activity is decreased 
only in the aging hearts of 20 month-old mice by post-
translational nitrative modification. Interestingly our data 
shows that already at 12 month-old, when the deleterious 
effects of pro-oxidant mechanisms associated to aging 
are not completely established, are enough to detect and 
increase in Trx1 nitration and a consequent inactivation. 
It is probable that these post-translational modifications 
are related to the fact that no protection was evidenced 
in the size of the infarct. Neither were changes in the 
phosphorylation of Akt and GSK-3β in middle-aged mice.
Regarding Akt/p-Akt Ser473 in particular, Adluri et 
al. [19] demonstrated that Trx1 overexpression induces 
Akt-signaling pathway compared to WT mice during 
ischemic stress, and this could be related to a reduction 
in oxidative stress. These authors used a chronic model 
of myocardial infarction and showed that the Akt was 
phosphorylated several days after the ischemia insult. 
However, our research is the first that involves Akt as the 
probable target for thioredoxin to provide protection in 
an ischemia/reperfusion in vitro model in an acute way. 
This was supported by the fact that in DN-Trx1 mice 
phosphorylation of Akt and GSK-3β was not observed 
and therefore the infarct size was not reduced. Regarding 
interactions, it has been demonstrated that Trx1 is capable 
of indirectly phosphorylating Akt in other pathologies 
such as myocardial remodelling and cancer [21, 25, 26]. 
This protein has been extensively studied and has a major 
role in physiological and pharmacological protection 
mechanisms; it is also part of the RISK-pathway protection 
system [25, 27, 28]. A possible mechanism by which Trx 
relates to Akt is through PTEN, because it has been shown 
that Trx1 inhibits PTEN [29], as this mediator modulates 
activation of PI3K/Akt complex triggering intracellular 
events that confer protection against I/R injury [28]. 
Figure 5: We showed DN-Trx1 mice results in order to confirm that the cardioprotection conferred by Trx1 involves 
Akt and GSK-3β inhibition/phosphorylation. nfarct size (Panel A), Trx1 expression (Panel C), p-Akt Ser473 (Panel D) and p-GSK-
3β Ser9 (Panel E) were similar between wild type (WT) and in dominant negative for Trx1 (DN-Trx1) in young and middle-aged mice. 
Panel B shows representative slide of infarct size. Panel F shows Ponceau S-stained blot, as loading control, and Akt/ GSK-3β representative 
blots. Data are represented as mean +/- SEM.
Oncotarget11895www.impactjournals.com/oncotarget
A limitation to our study is that we did not evaluate the 
interaction between PTEN and Trx1, nevertheless when 
we used DN-Trx1mice we could not detect neither 
cardioprotection nor activation of pro-survival proteins. 
Therefore, our data suggest that overexpression of Trx1 
protects the myocardium against ischemia/reperfusion 
injury by activating Akt and GSK-3β.
Our results confirm that the protection conferred by 
the overexpression of Trx1 would be at least partially due 
to inactivation of GSK-3β, given that in DN-Trx1 the lack 
of GSK-3β phosphorylation showed that this pro-survival 
protein was not activated [30]. To our knowledge, this is 
a novel finding since, no studies have assessed if Trx1 has 
an effect on GSK-3β in an acute way, once reperfusion is 
initiated, in young and middle-aged mice comparatively. 
Unlike our findings, Schenkel et al. [20] demonstrated 
that after myocardial infarction, even though Trx1 appears 
to make an important contribution to the reduced H2O2 
concentration, is not enough to produce modifications in 
GSK-3β in the early stages in a chronic model without 
reperfusion. This difference is important; given that Zhai 
et al. [30] demonstrated that the inhibition of GSK-3β does 
not produce a cardioprotective effect, but exacerbates the 
ischemic injury in a mice model with ischemia without 
reperfusion. However, it does have a protective effect 
against ischemic injury followed by reperfusion through 
the modulation of autophagy [30]. Thus, in concordance 
with our findings, the inactivation of GSK-3β would have 
a protective effect in I/R models, like our experimental 
model. This inactivation of GSK-3β would have a 
beneficial effect in young mice overexpressing Trx1; 
meanwhile there is no evidence of phosphorylation or 
infarct reduction in middle-aged Trx1 and in DN-Trx1 
mice.
In agreement with previous studies using isolated 
hearts mice preparations [31] in our study, overexpression 
of Trx1 in young mice reduced infarct size but was unable 
to improve ventricular function (contractile state and 
myocardial stiffness).The absence of improvement of 
LV function in our study may be due to the presence of 
myocardial stunning areas peripheral to the infarct zone 
[31, 32]. In this sense, it has been well shown that the 
presence of a certain degree of post-ischemic dysfunction 
(stunned myocardium) reverts approximately after 48/72 
hours of reperfusion; therefore the change in infarct size 
in acute experiments does not influence significantly the 
ventricular function [32]. 
In summary, Trx1 overexpression reduced, 
as expected, infarct size in young mice and this 
cardioprotection included an increase of Akt and GSK-3β 
phosphorylation. The lack of protection in middle-aged 
mice was related to the reduction in Trx1 activity and 
increase in Trx1 nitration. These data, and the fact that in 
DN-Trx1 we did not detect a reduction in the infarct size, 
suggest a cardioprotective role of Trx1 activating Akt and 
GSK-3β in an acute way.
MATERIALS AND METHODS
Animal care
All procedures performed in these studies 
involving animals were in accordance with the ethical 
standards of the Animal Care and Research Committee 
of the University of Buenos Aires (CICUAL UBA # 
0037016/2012). FVB mice were housed in ventilated 
cages with a 12 hours light/dark cycle and controlled 
temperature (20-22°C), and fed with normal chow and 
water ad libitum.
Experimental protocols
Three and twelve month-old male hearts from: a) 
transgenic mice with cardiac- specific overexpression 
of Trx1 (generated on an FVB background using the 
α-myosin heavy chain promoter to achieve cardiac-specific 
expression), b) DN-Trx1 mice was generated by mutation 
of 32Cys and 35Cys of hTrx1 to Ser using QuikChange 
(Stratagene, La Jolla, California, USA) [33]. This redox 
inactive mutant of Trx1 works as a dominant negative for 
endogenous Trx1 in mice hearts, and c) its corresponding 
wild type mice (FVB) were randomized into six groups: 
1) wild type young (WT-Y, n = 8); 2) Trx1 young (Trx1-Y, 
n = 7); 3) wild type middle-aged (WT-MA, n = 7); 4) Trx1 
middle-aged (Trx1-MA, n = 6); 5) DN-Trx1 young (DN-
Trx1-Y, n = 8); and 6) DN-Trx1middle-aged (DN-Trx1-
MA, n = 7). For the middle-aged group, mice should be 
at least 10 month-old; the upper age limit for the middle-
aged group is typically 14-15 month-old [34]. For this 
reason we decided to use 12 month-old as middle-aged 
mice. 
Isolated mice heart
In all groups we used isolated mice hearts perfused 
according to Langendorff technique and performed 
30 minutes of global ischemia and 120 minutes 
of reperfusion. The mice were anesthetized by an 
intraperitoneal injection of sodium pentobarbital (150mg/
Kg) and sodium heparin (500 IU/kg bow, i.p). After 
ensuring sufficient depth of anesthesia, hearts were excised 
and the aorta was immediately cannulated with a 21 gauge 
cannula. After that, hearts were perfused according to 
Langendorff technique with Krebs bicarbonate-buffered 
solution containing (in mM): NaCl 118.5, KCl 4.7, 
NaHCO3 24.8, KH2PO4 1.2, Mg SO4 1.2, CaCl2 1.5 and 
glucose 10. This solution was continuously bubbled with 
95% O2 and 5% CO2 (pH = 7.4) at 37 °C. During this 
time a small fluid-filled balloon, which was connected 
via a thin plastic catheter (P50) to a pressure transducer 
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(Deltram II, Utah Medical System), was inserted into 
the left ventricle (LV) via the left atrium. The catheter 
with the transducer was positioned in such a way that it 
secured the position of the balloon in the left ventricle 
for measurement of LV pressure. The latex balloon was 
filled with water to achieve an LV end diastolic pressure 
of 8-10 mmHg (LVEDP). Two electrodes were sutured 
and connected to a pacemaker to produce a constant heart 
rate of 472±30 beats/min. We also recorded the coronary 
perfusion pressure (CPP) through a pressure transducer 
connected to the perfusion line. All hearts were perfused 
at constant flow at 4.01±0.27 ml/min. Coronary flow was 
adjusted to obtain a CPP of 73±3 mmHg during the initial 
stabilization period and was then maintained constant 
throughout the experiment. LVDP and LV+dP/dtmax were 
used as contractile state indexes. LVEDP, a myocardial 
stiffness index in the isovolumic heart, was also measured.
Infarct size measurement
The assessment of the infarct size was performed 
using 2,3,5-triphenyltetrazolium chloride (TTC). After 
120 minutes of reperfusion, the hearts were frozen and cut 
into 1 mm transverse slices from apex to base. Sections 
were incubated for 20 minutes in 1% TTC (pH 7.4, 37 °C) 
and then immersed in 10% formalin. With this technique, 
viable sections were stained red, while the non-stained 
sections corresponded to the infarct area. Sections were 
traced to acetate sheets and planimetered (Image Pro Plus, 
version 4.5). Infarct size was expressed as a percentage of 
the left ventricular area.
Insulin reduction assay for Trx1
The activity of Trx1 in the heart was determined 
by the insulin reduction assay, according to the method 
described by Holmgren and Bjornstedt (1995) with a slight 
modification. Hearts form TG Trx1 young mice (n = 5) and 
MA (n = 6) were homogenated with ice-cold phosphate 
buffered saline (PBS) containing 10 µg/ml PMSF 
(phenylmethanesulfonylfluoride), 0.5 µg/ml aprotinin 
and 0.5 µg/ml leupeptin. An equal amount of protein (50 
µg) in a volume of 13.28 µl was preincubated with 3.32 
µl of the dithiothreitol (DTT) activation buffer (100 mM 
Tris-Cl [pH 7.5], 2 mM ethylenediaminetetraacetic acid 
(EDTA), 1 mg/ml bovine serum albumin (BSA), and 2 
mM DTT) at 37 °C for 15 minutes. The samples were 
then mixed with 183.3 µl of reaction mixture (100 mM 
Tris-Cl [pH 7.5], 2.0 mM EDTA, 1.0 µg human Trx-
reductase and 140 µM insulin) and were incubated at 25 
°C. Reaction is started by adding nicotinamide adenine 
dinucleotide phosphate (NADPH) (0.2 mM). As a control, 
the samples were mixed with the reaction mixture without 
Trx-reductase. Changes in absorbance in the absence of 
Trx-reductase were subtracted from those in the presence 
of Trx-reductase [33].
Western blot
We performed additional experiments to obtain 
hearts samples (n = 5 in each group) in order to Western 
blot analysis. Heart tissue was homogenized in ice for 
approximately 2 minutes with extraction buffer (pH 
7.4), composed of: Tris 1.2 mM, NaCl 0.36 mM, sodium 
dodecyl sulfate (SDS) 0.1%, Triton 1%, DTT 0.2 mM, 
protease and phosphatase inhibitors cocktail (Thermo 
Scientific) at a rate of 500 μL buffer every 150 mg of 
tissue using a PRO 200 Scientific INC homogenizer. 
Subsequently, homogenates were centrifuged at 12000 
rpm during 20 minutes at 4 °C. The supernatant protein 
concentration was quantified with Bradford method. 
After protein quantification 50 µg of each sample were 
separated by 16% Tricine-SDS-PAGE gels for Trx1 
and cardiac nitration, and by 12% SDS-PAGE gels for 
Akt and GSK-3β. Then the gels were transferred to a 
polyvinylidene fluoride (PVDF) membrane (Thermo 
Scientific) that was later blocked with 5% BSA for two 
hours at room temperature. Subsequently, the membrane 
was incubated with anti-Trx1 (1:1000) (Cell Signaling), 
anti-3-nitrotyrosine antibody (1:2000), anti-p-Akt for 
serine residue 473 and threonine residue 308 (1:1000) 
(Cell Signaling), and anti-p-GSK-3β for serine residue 
9 (1:1000) (Cell Signalling) over night at 4 °C with 
agitation. It was later incubated with anti-rabbit secondary 
antibody conjugated with horseradish peroxidase (HRP, 
1:15000) (Millipore) for an hour at room temperature. 
The membrane was developed with photographic plates 
(Kodak) and Super Signal West Pico Chemiluminescent 
Substrate (Thermo Scientific). Proteins expression was 
quantified by densitometry with Image Gauge 4.0 software 
(Fujifilm) compared to the charge control values, Ponceau 
Red staining (Sigma) measured in the same membranes 
and was used as loading control. 
Statistical analysis
Data are expressed as mean ± standard error of the 
mean (SEM). Inter-group comparisons were performed 
using analysis of variance and then the Bonferroni test for 
multiple comparisons. p < 0.05 was considered statistically 
significant.
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